Recombinant Dna Technique Included In Method Of Making A Protein Or Polypeptide Patents (Class 435/69.1)
-
Patent number: 11168310Abstract: Disclosed herein are compositions and methods of treating disclosure provides for compounds for use in treating Mitochondrial Neurogastrointestinal Encephalopathy Syndrome (MNGIE). In some embodiments, the compounds have cell penetrating activity and thymidine phosphorylase activity. In certain embodiments, the compounds disclosed herein comprise: a) at least one cell-penetrating peptide (CPP) moiety; and b) a thymidine phosphorylase, or an active fragment or analog thereof (TP), wherein the CPP is coupled, directly or indirectly, to TP.Type: GrantFiled: March 17, 2020Date of Patent: November 9, 2021Assignee: Entrada Therapeutics, Inc.Inventors: Natarajan Sethuraman, Jason Ruth, Lou A. Tartaglia, Dehua Pei, Ziqing Qian
-
Patent number: 11155781Abstract: The present disclosure describes methods of maintaining the phenotype of differentiated cells. Generally, the natural environment of the body is replicated for the differentiated cell. The differentiated cell is plated on a cell culture substrate comprising a laminin, such as laminin-521 or laminin-511. The substrate may also contain a cadherin. This maintains the phenotype of the differentiated cell.Type: GrantFiled: November 14, 2016Date of Patent: October 26, 2021Assignee: BIOLAMINA ABInventors: Karl Tryggvason, Karl Kristian Tryggvason, Anna Domogatskaya
-
Patent number: 11142756Abstract: The disclosure relates to acetyl-CoA carboxylase (ACC) variants and host cells expressing them for the production of malonyl-CoA derived compounds including fatty acid derivatives. Further contemplated are methods of producing increased amounts of malonyl-CoA derived compounds and related cell cultures.Type: GrantFiled: February 26, 2020Date of Patent: October 12, 2021Assignee: Genomatica, Inc.Inventors: Derek L. Greenfield, Donald E. Trimbur, Andreas W. Schirmer, Cindy Chang, Behnaz Behrouzian, Jessica Winger
-
Patent number: 11136549Abstract: The invention is directed to modified T cells, methods of making and using isolated, modified T cells, and methods of using these isolated, modified T cells to address diseases and disorders. In one embodiment, this invention broadly relates to TCR-deficient T cells, isolated populations thereof, and compositions comprising the same. In another embodiment of the invention, these TCR-deficient T cells are designed to express a functional non-TCR receptor. The invention also pertains to methods of making said TCR-deficient T cells, and methods of reducing or ameliorating, or preventing or treating, diseases and disorders using said TCR-deficient T cells, populations thereof, or compositions comprising the same.Type: GrantFiled: April 10, 2017Date of Patent: October 5, 2021Assignee: THE TRUSTEES OF DARTMOUTH COLLEGEInventor: Charles L. Sentman
-
Patent number: 11136586Abstract: The invention relates to an in vitro cell-free expression system incorporating a novel inorganic polyphosphate-based energy regeneration system. In certain embodiments, the invention includes a cell-free expression system where the cellular energy source, ATP, is regenerated from inorganic polyphosphate using a dual enzyme system. In this embodiment, this dual enzyme system may include thermostable Adenosyl Kinase, and/or Polyphosphate Kinase enzymes.Type: GrantFiled: January 2, 2018Date of Patent: October 5, 2021Assignee: NTxBio, LLCInventors: Alexander Koglin, Michael Humbert
-
Patent number: 11123369Abstract: Disclosed herein are methods of engineering a bi-specific T-cell expressing chimeric antigen receptors for promoting the in vivo expansion and activation of an effector cell and a second chimeric antigen receptor or TcR specific for a ligand on a tumor. Methods of administering to subjects in need, bi-specific chimeric antigen receptor bearing cells are also provided.Type: GrantFiled: November 3, 2020Date of Patent: September 21, 2021Assignee: Seattle Children's HospitalInventor: Michael C. Jensen
-
Patent number: 11122817Abstract: The present invention provides a protein material and food ingredient from a sustainable and stable source. The sustainable and stable source of the food or food ingredient is cellular biomass, for example an algal or microbial biomass. The invention discloses that the cellular biomass can be subjected to a series of steps to derive the protein material and food or food ingredient, which has high nutritional content and has pleasing organoleptic properties.Type: GrantFiled: January 25, 2016Date of Patent: September 21, 2021Assignee: Smallfood Inc.Inventors: George C. Rutt, James H. Flatt, Peter Domaille, Gerardo V. Toledo, Daniel G. Dueppen
-
Patent number: 11123579Abstract: The detergent product for cosmetic use, comprises: a base compound having a detergent action; spores of probiotic bacteria mixed with the base compound; bacteriophage elements mixed with the base compound and having bactericide activity on predetermined undesired bacterial species present, the bacteriophage elements, in cooperation with the spores of probiotic bacteria, being able to carry out a combined and synergic action against damaging micro-organisms. Use of the detergent product is also described, for cleansing of the skin, skin adnexa (hair, nails, body hair, beard), of the oral cavity, mucosa or the teeth.Type: GrantFiled: September 21, 2017Date of Patent: September 21, 2021Assignee: COPMA S. C. A. R. L.Inventors: Alberto Rodolfi, Elisabetta Caselli
-
Patent number: 11110176Abstract: Embodiments of the disclosure pertain to compositions containing (i) one or more non-antifreeze proteins or cell components or cells and (ii) one or more antifreeze proteins (AFPs), mimetics thereof, and/or analogs thereof, and a method of stabilizing a biologic (e.g., a protein, microbe, cell component or cell) against temperature stress and aggregation. The AFP may be selected from known antifreeze polypeptides and antifreeze peptides, analogs and mimetics of antifreeze proteins, active fragments of such antifreeze proteins, polypeptide and peptide mimetics, antifreeze peptoids and polymers, and combinations thereof. The non-antifreeze protein, cell component or cell comprises a known protein, cell component or cell used in the pharmaceutical, medical, agricultural, veterinary and/or food industry(ies). The AFP protects the function of the non-antifreeze protein, microbe(s), cell component(s) or cell(s) under temperature stress (e.g., a temperature of ?20-60° C.).Type: GrantFiled: November 22, 2017Date of Patent: September 7, 2021Assignee: The Board of Trustees of the California State UniversityInventor: Xin Wen
-
Patent number: 11111283Abstract: The present invention provides new protease resistant polypeptides, as well as compositions and methods for treating, ameliorating or preventing conditions related to joint damage, including acute joint injury and arthritis.Type: GrantFiled: February 7, 2019Date of Patent: September 7, 2021Assignee: NOVARTIS AGInventors: Kristen Johnson, Jian Shi
-
Patent number: 11104711Abstract: Compounds are provided herein for inducing weight loss and for treating diabetes, dyslipidemia, NASH and/or obesity. Also provided are pharmaceutical compositions containing such compounds and therapeutic uses of such compounds and compositions, where such compounds act as GDF15 agonists with extended time of action and other advantageous properties.Type: GrantFiled: March 29, 2019Date of Patent: August 31, 2021Assignee: Eli Lilly and CompanyInventors: Malgorzata Donata Gonciarz, Victor H. Obungu, Richard Todd Pickard
-
Patent number: 11098321Abstract: The invention provides recombinant DNA molecules that are unique to the maize MON 87419 event and transgenic maize plants, plant parts, seeds, cells, and agricultural products containing the MON 87419 event as well as methods of using and detecting the maize MON 87419 event. Transgenic maize plants containing the MON 87419 event exhibit tolerance to dicamba and glufosinate herbicides.Type: GrantFiled: August 23, 2018Date of Patent: August 24, 2021Assignee: Monsanto Technology LLCInventors: Wen C. Burns, Michael E. Goley, Jintai Huang, Melinda C. McCann, Aihua Shao, Oscar C. Sparks, Martin A. Stoecker, Liping Wei
-
Patent number: 11098329Abstract: One aspect of the invention relates to a mutant polypeptide comprising the amino acid sequence of Escherichia coli tetracycline efflux pump A (TetA). Another aspect of the invention relates to a polynucleotide encoding a polypeptide of TetA, a fragment thereof, or a mutant thereof. Another aspect of the invention relates to a first expression plasmid vector comprising one or more first polynucleotides encoding a first polypeptide comprising a tetracycline efflux pump polypeptide, a fragment thereof or a mutant thereof, one or more second polynucleotides independently selected from the group consisting of a third polynucleotide encoding a third polypeptide comprising a lysine decarboxylase polypeptide, a fragment thereof or a mutant thereof, and a fourth polynucleotide encoding a fourth polypeptide comprising a lysine biosynthesis polypeptide, a fragment thereof or a mutant thereof.Type: GrantFiled: July 17, 2019Date of Patent: August 24, 2021Assignees: CATHAY BIOTECH INC., CIBT AMERICA INC.Inventors: Howard Chou, Xiucai Liu
-
Patent number: 11098107Abstract: The present disclosure relates to antibodies and antibody conjugates having one or more site-specific mutations in the CH2 domain of the heavy chain. The antibody variants disclosed herein can have improved characteristics (e.g., thermal stability, antibody yields, antibody titers, cell-killing) relative to a parent or wild type antibody, including aglycosylated parent or wild type antibodies. Pharmaceutical compositions, diagnostic compositions and kits comprising the same, as well as methods of using these compositions and kits for therapeutic and diagnostic purposes, are also described.Type: GrantFiled: June 14, 2017Date of Patent: August 24, 2021Assignee: SUTRO BIOPHARMA, INC.Inventors: Daniel Calarese, Gang Yin
-
Patent number: 11098363Abstract: The disclosure provides nucleic acid molecules, including cDNA, comprising an alteration that encodes a loss-of-function cornulin (CRNN) protein. The disclosure also provides isolated and recombinant human loss-of-function cornulin protein variants that comprise a truncation at a position corresponding to position 79. The truncation, and the nucleic acid molecules encoding this change, associate with skin disorders such as, for example, psoriasis, eczema, or atopic dermatitis. The disclosure also provides methods for determining whether a subject has or has a risk of developing a skin disorder, based on the identification of such alterations in the nucleic acid molecules encoding CRNN. Subjects at risk for or who have a skin disorder may be treated with an agent effective to treat the skin disorder.Type: GrantFiled: October 16, 2018Date of Patent: August 24, 2021Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Claudia Gonzaga-Jauregui, Kavita Praveen
-
Patent number: 11098091Abstract: Mutant M-CSF protein, comprising ?v?3 integrin binding motif and pharmaceutical compositions comprising same, are provided. Further, use of the composition for the treatment and or prevention of diseases associated with increased bone resorption are provided.Type: GrantFiled: August 17, 2017Date of Patent: August 24, 2021Assignees: THE NATIONAL INSTITUTE FOR BIOTECHNOLOGY IN THE NEGEV LTD., B. G. NEGEV TECHNOLOGIES AND APPLICATIONS LTD., AT BEN-GURION UNIVERSITYInventors: Niv Papo, Noam Levaot, Yuval Zur, Lior Rosenfeld
-
Patent number: 11093547Abstract: Devices, methods, and systems for encoding data as DNA are provided. An encoder device can include an encoder engine configured to encode a data file having a bit sequence encoding data and further configured to generate a virtual DNA (VDNA) sequence of virtual nucleotide bases (Vnb) that reversibly encodes the bit sequence of the data file, divide the VDNA sequence into a plurality of VDNA fragments, associate each VDNA fragment with an archive library sequence (Arc_SEQ), and generate a read instruction (READ) sequence of differences between each VDNA fragment and each associated Arc_SEQ including sufficient instruction to facilitate regeneration of each VDNA fragment from each associated Arc_SEQ. A codeword sequence (Code_SEQ) is additionally generated for each VDNA fragment comprising a codename identifying the associated Arc_SEQ, the READ sequence associated with the VDNA fragment, and an index sequence (Idx_SEQ) including an index mapping of the VDNA fragment in the VDNA sequence.Type: GrantFiled: June 19, 2018Date of Patent: August 17, 2021Assignee: Intel CorporationInventors: Xing Su, Kai Wu, Noureddine Tayebi, Grace Credo
-
Patent number: 11091533Abstract: Provided herein are peptides comprising a mutated fragment of a wild-type protease-activated receptor-2 (PAR2). The peptides comprising a hydrophobic moiety can penetrate the cell membrane and act as an antagonist of PAR2. Also provided herein are compositions and cells comprising the peptides and methods of using the peptides.Type: GrantFiled: November 11, 2016Date of Patent: August 17, 2021Assignee: Oasis Pharmaceuticals, LLCInventor: Richard Looby
-
Patent number: 11085045Abstract: The present invention provides functional aptamer-comprising tRNA molecules, useful in the study of tRNA and ribosomal activity.Type: GrantFiled: November 16, 2016Date of Patent: August 10, 2021Assignees: Anima Biotech Inc., Thomas Jefferson UniversityInventors: Iris Alroy, Ya-Ming Hou, Howard Gamper
-
Patent number: 11084860Abstract: The present invention relates to modified recombinant human MIS protein which has improved cleavage and increased bioactivity and increased potency as compared to wild-type human MIS protein. Other aspects of the invention relate to methods to prevent and treat cancers, such as cancers that express the MIS receptor type II (MISRII) by administering to a subject a composition comprising a recombinant human MIS protein. Another aspect of the present invention relates to methods to lower plasma androgen levels in a subject, and/or for the treatment of a subject with a disease characterized by excess androgen. Another aspect provides pharmaceutical compositions and kits and methods for use comprising a recombinant human MIS protein. Another aspect of the present invention relates to methods to decrease the dose of a chemotherapeutic agent by administering the chemotherapeutic agent with the recombinant MIS protein that lowers the effective dose of the chemotherapeutic agent.Type: GrantFiled: March 12, 2014Date of Patent: August 10, 2021Assignees: THE GENERAL HOSPITAL CORPORATION, MASSACHUSETTS EYE AND EAR INFIRMARYInventors: Patricia K. Donahoe, Demetrios Vavvas, David Pepin, Mien Van Hoang
-
Patent number: 11085064Abstract: A system for automated microorganism identification and antibiotic susceptibility testing comprising a reagent cartridge, a reagent stage, a cassette, a cassette, stage, a pipettor assembly, an optical detection system, and a controller is disclosed. The system is designed to dynamically adjust motor idle torque to control heat load and employs a fast focus process for determining the true focus position of an individual microorganism. The system also may quantify the relative abundance of viable microorganisms in a sample using dynamic dilution, and facilitate growth of microorganisms in customized media for rapid, accurate antimicrobial susceptibility testing.Type: GrantFiled: February 28, 2020Date of Patent: August 10, 2021Assignee: Accelerate Diagnostics, Inc.Inventors: Austin Ashby, Wayne Showalter, Jasmin Cote
-
Patent number: 11072830Abstract: The present invention relates to methods and systems for assessing the overall risk of a human female subject for developing a breast cancer phenotype. In particular, the present invention relates to combining clinical risk assessment and genetic risk assessment to improve risk analysis.Type: GrantFiled: November 15, 2017Date of Patent: July 27, 2021Assignee: GENETIC TECHNOLOGIES LIMITEDInventors: David A. Hinds, Bryan Walser
-
Patent number: 11072666Abstract: The present invention provides anticancer agents comprising as an active ingredient a bispecific antibody that comprises a domain comprising a glypican 3-binding antibody variable region, a domain comprising a T cell receptor complex-binding antibody variable region, and common L chains that can enhance the affinity for the two antigens, as well as pharmaceutical compositions comprising the bispecific antibody as an active ingredient, the compositions being for use in combination with other anticancer agents. The bispecific antibodies are novel molecules which are produced with high efficiency and have strong anti-tumor activity as well as safety and excellent pharmacodynamics. The bispecific antibodies can be expected to be applied to various cancers.Type: GrantFiled: February 24, 2017Date of Patent: July 27, 2021Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Yasuko Kinoshita, Yumiko Kawai, Toshiaki Tsunenari, Takahiro Ishiguro, Mika Endo, Yuji Sano
-
Patent number: 11074993Abstract: Methods and computer apparatuses are disclosed for processing genomic data in at least partially automated workflows of modules. A method comprises: specifying a source from which nucleic acid sequence(s) are to be obtained; selecting module(s) for processing data, including at least one module for processing the one or more nucleic acid sequences; presenting, in a graphical user interface, graphical components representing the source and the module(s) as nodes within a workspace; receiving, via the graphical user interface, inputs arranging the source and the module(s) as a workflow comprising a series of nodes, the series indicating, for each particular module, that output from one of the source or another particular module is to be input into the particular module; generating an output for the workflow based upon the nucleic acid sequence(s) by processing each module in an order indicated by the series.Type: GrantFiled: August 16, 2019Date of Patent: July 27, 2021Assignee: PALANTIR TECHNOLOGIES INC.Inventors: Lekan Wang, Hyunghoon Cho, Abimanyu Raja, Elizabeth Caudill
-
Patent number: 11072647Abstract: An isoform of the TGF beta receptor II comprising a sequence of about of 80 amino acids and lacking a transmembrane domain. The isoform comprises the amino acid sequence set forth in SEQ ID No. 12. The isoform may have the amino acid sequence set forth in SEQ ID No. 2 or sequences having at least 85% sequence identity to the sequence set forth in SEQ ID No. 2. A fusion peptide is provided comprising an isoform of the TGF beta II receptor fused to a ligand, wherein a vector comprising the fusion peptide is used to treat cancer and/or hepatic fibrosis. An antibody binding the soluble isoform of the TGF beta II receptor is provided. The antibody binds the amino acid sequence shown in SEQ ID No. 12 and is used in in vitro methods.Type: GrantFiled: October 29, 2018Date of Patent: July 27, 2021Assignees: Onsejo Nacional DE Investigation Cientiticay Tecnica, Fundocion ArticulaInventors: Ana Romo, Anabela Belen La Colla, Matias Adan Preisegger, Marcela Soledad Bertolio, Ricardo Alfredo Dewey, Pamela Daiana Vazquez, Andrea Nancy Chisari, Tania Melina Rodriguez, Benito Jorge Velasco Zamora
-
Patent number: 11071772Abstract: The present invention relates to a method for preventing and treating tissue and organ fibrosis, comprising administering an effective amount of plasminogen to a subject.Type: GrantFiled: June 19, 2017Date of Patent: July 27, 2021Assignee: Talengen International LimitedInventor: Jinan Li
-
Patent number: 11066653Abstract: The present invention is directed to a producing a DNA methyltransferase in a recombinant host cell, wherein the DNA methyltransferase methylates DNA resulting in a DNA containing 5-methylcytosine within the recognition sequence GCNGC and wherein the DNA methyltransferase comprises less than (35) amino acid residues between amino acid residue (72) and amino acid residue (106) according to the numbering of SEQ ID NO: 33. Furthermore, the present invention is directed to the use of such DNA methyltransferase for the production of bacterial transformants comprising the steps of (a) introducing into a first bacterial host cell a polynucleotide comprising a polynucleotide sequence encoding the DNA methyltransferase to produce a methylated DNA and (b) transferring the methylated DNA from the first bacterial host cell into a second bacterial host cell, wherein the second bacterial host cell comprises a restriction endonuclease able to degrade the DNA but unable to degrade the methylated DNA.Type: GrantFiled: July 11, 2018Date of Patent: July 20, 2021Assignee: BASF SEInventors: Max Fabian Felle, Stefan Seemayer
-
Patent number: 11053288Abstract: The present invention provides methods and compositions for generating transgenic animals, including transgenic mammals, as well as plasma cells that allow for cell surface capture of secreted immunoglobulin molecules produced endogenously in the plasma cells.Type: GrantFiled: February 3, 2017Date of Patent: July 6, 2021Assignee: TRIANNI, INC.Inventors: Nigel Killeen, Christoph Hasenhindl, Bao Duong
-
Patent number: 11046736Abstract: The instant invention relates to filamentous fungal host cells producing and secreting a heterologous polypeptide of interest, said mutant host cell comprising and expressing a mutated ireA gene or a homologue thereof encoding a modified IreA polypeptide or a homologue thereof, said modified IreA polypeptide or homologue thereof comprising amino acid substitutions in 5 positions corresponding to positions 81 and 84 in the Aspergillus niger IreA amino acid sequence shown in SEQ ID NO:16, as well as methods of producing a polypeptide of interest in said cells and methods for constructing said cells.Type: GrantFiled: July 19, 2017Date of Patent: June 29, 2021Assignee: Novozymes A/SInventors: Hiroshi Teramoto, Kaihei Kojima, Preethi Ramaiya
-
Patent number: 11046942Abstract: The present invention provides engineered DNase proteins (including DNase1-like 3 and DNase1) that are useful for treating conditions characterized by neutrophil extracellular trap (NET) accumulation and/or release. In some aspects, the invention provides compositions and methods for preventing or treating vascular occlusion involving NETs. As demonstrated herein, NETs participate in a non-canonical mechanism for vascular occlusion, which is not dependent on fibrin or platelets.Type: GrantFiled: September 11, 2020Date of Patent: June 29, 2021Assignee: NEUTROLIS, INC.Inventors: Tobias A. Fuchs, Miguel Jiménez-Alcázar, Josephine Göbel, Hanna Englert
-
Patent number: 11046943Abstract: The present invention provides engineered DNase proteins (including DNase1-like 3 and DNase1) that are useful for treating conditions characterized by neutrophil extracellular trap (NET) accumulation and/or release. In some aspects, the invention provides compositions and methods for preventing or treating vascular occlusion involving NETs. As demonstrated herein, NETs participate in a non-canonical mechanism for vascular occlusion, which is not dependent on fibrin or platelets.Type: GrantFiled: October 12, 2020Date of Patent: June 29, 2021Assignee: NEUTROLIS, INC.Inventors: Tobias A. Fuchs, Miguel Jiménez-Alcázar, Josephine Göbel, Hanna Englert
-
Patent number: 11046772Abstract: The present invention provides a method of cell culture comprising adding a cell-containing seed medium to an initial medium and starting to culture the cell in the initial medium, wherein the initial medium has an organism-derived culture medium additive added thereto and the amount of the C-terminal amidated species in the produced protein is controlled by the copper content of the initial medium at the start of cell culture.Type: GrantFiled: March 25, 2016Date of Patent: June 29, 2021Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Seiko Yamamoto, Hiroyuki Doi, Isamu Terashima
-
Patent number: 11046975Abstract: The present invention relates to a bicistronic expression vector for antibody expression, an animal cell transfected with the expression vector, and a method for producing an antibody including culturing the animal cell, in which the expression vector includes a first expression cassette including ‘promoter-UTR-intron-antibody light chain gene-polyA’ and a second expression cassette including ‘promoter-UTR-intron-antibody heavy chain gene-internal ribosome entry site (IRES)-amplification gene-polyA’. An expression vector capable of expressing a desired antibody with high efficiency can be constructed using the bicistronic expression vector including an intron for antibody expression according to the present invention, and the expression vector can produce the antibody by culturing the transfected animal cell with stability and high efficiency.Type: GrantFiled: October 7, 2014Date of Patent: June 29, 2021Assignee: PRESTIGE BIOPHARMA PTE. LTD.Inventors: Soo Kwang Kim, Young Min Kim, Yong Gyu Son, Yong Ho Ahn, Dong Heon Lee, Yang Soon Lee, Hee Jung Jun, Yu Bin Choi, Eun A Kim
-
Patent number: 11034966Abstract: The invention relates to, in part, improved methods for the production of beta-lactamase using Escherichia coli (E. coli) cells. High yield production of beta-lactamase is achieved using methods of the invention.Type: GrantFiled: August 27, 2015Date of Patent: June 15, 2021Assignee: Synthetic Biologics, Inc.Inventors: Andrew Bristol, Michael Kaleko, Steven Hubert
-
Patent number: 11028128Abstract: The invention disclosed herein relates to peptide inhibitors for transthyretin (TTR) aggregation and methods of inhibiting TTR aggregation, cytotoxicity, and/or TTR amyloidosis. Illustrative embodiments of the invention include a composition of matter comprising at least one peptide designed to inhibit the aggregation of TTR, with this peptide typically being coupled to a heterologous amino acid tag. A pharmaceutically acceptable carrier selected to be compatible with the inhibitory peptide may also be included. A method for blocking or inhibiting the aggregation of transthyretin TTR is also provided. The method comprises combining TTR with an effective amount of an inhibitory peptide or pharmaceutical composition, so that TTR aggregation and/or cytotoxicity is blocked or inhibited.Type: GrantFiled: June 29, 2017Date of Patent: June 8, 2021Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: David S. Eisenberg, Lorena Saelices Gomez
-
Patent number: 11028132Abstract: Coronavirus disease 2019 (COVID-19 or COVID-2) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Common symptoms include fever, cough, and shortness of breath. The virus is mainly spread during close contact and via respiratory droplets produced when people cough or sneeze. Respiratory droplets may be produced during breathing but the virus is not generally airborne. A half-life optimized fusion composition linked by a Half-Life Optimizing (H-Lo) linker comprising of a receptor binding domain (RBD), a half-life extending domain (LED), wherein the LED is any one of a monoclonal antibody, single domain antibody, nanobody, antibody fragment, or combination thereof and the H-Lo linker with an X+7 amino acid length fusing the RBD C-terminus with the LED N-terminus (RBD-LED fusion) is discussed in the invention.Type: GrantFiled: July 24, 2020Date of Patent: June 8, 2021Inventor: Yitzhak Rosen
-
Patent number: 11020457Abstract: The effects of hepcidin treatment on mitigating ischemia reperfusion injury (IRI) and acute kidney injury (AKI) by decreasing iron availability and ROS-mediated cell death were tested. Wild type (WT) C57Bl/6 and hepcidin knock out (Hamp?/?) mice were treated with saline or 50 ?g of hepcidin i.p. prior to bilateral renal IRI. Renal function, injury markers, histopathology, and inflammation were examined after 24 hours of reperfusion. In WT mice, IRI induced increases in serum and kidney non-theme iron levels, but hepcidin treatment induced sequestration of iron in the spleen and liver and prevented IRI-associated increases in serum and kidney non-heme iron. Kidney function was significantly better in hepcidin-treated mice, accompanied by less acute tubular necrosis and reduced infiltration of immune cells. Hepcidin treatment decreased kidney ferroportin expression and induced the expression of cytoprotectant, H-Ferritin, and was associated with less ROS and tubular epithelial apoptosis.Type: GrantFiled: May 17, 2018Date of Patent: June 1, 2021Assignee: University of Virginia Patent FoundationInventor: Sundararaman Swaminathan
-
Patent number: 11020477Abstract: A RNA vaccine containing a RNA molecule encoding an allergen or derivative thereof, in which the allergen is an allergen of Alnus glutinosa, Alternaria alternata, Ambrosia artemisiifolia, Apium graveolens, Arachis hypogaea, Betula verrucosa, Carpinus betulus, Castanea sativa, Cladosporium herbarum, Corylus avellana, Cryptomeria japonica, Cyprinus carpio, Daucus carota, Dermatophagoides pteronyssinus, Fagus sylvatica, Felis domesticus, Hevea brasiliensis, Juniperus ashei, Malus domestica, Quercus alba or Phleum pratense.Type: GrantFiled: January 20, 2017Date of Patent: June 1, 2021Assignee: BIONTECH RNA PHARMACEUTICALS GMBHInventors: Josef Thalhamer, Richard Weiss, Elisabeth Rosler, Sandra Scheiblhofer, Angelika Fruhwirth
-
Patent number: 11013800Abstract: The present disclosure relates generally to multi-specific Fab fusion proteins (MSFP) which comprise an antibody Fab fragment with both N-termini fused to a fusion moiety (fusion moiety A or B). MSFP containing the Fab fragment exhibit significantly reduced binding ability of the Fab fragment to the Fab target. Binding of the Fab to its target is restored when the MSFP is clustered on a cell surface by binding of the fusion moieties to their target. The reduced binding of the Fab to its target, especially when presented on a cell surface in its native state, absent fusion moiety binding provides advantages such as: reduced side effects and allows desirable pharmacological effects of selectivity and specificity in a controlled manner.Type: GrantFiled: September 5, 2014Date of Patent: May 25, 2021Assignee: Evive Biotech Ltd.Inventor: Hongxing Zhou
-
Patent number: 11015172Abstract: The invention relates to a method for culturing a subpopulation of circulating epithelial tumour cells from a body fluid of a human or animal suffering from an epithelial tumour, wherein cells contained in the body fluid each containing at least one cell nucleus are separated from the body fluid and cultured over at least 24 hours in suspension, with formation of spheroids.Type: GrantFiled: August 2, 2013Date of Patent: May 25, 2021Inventors: Ulrich Pachmann, Katharina Pachmann
-
Patent number: 11008373Abstract: The invention relates to novel designer osteogenic proteins having altered affinity for a cognate receptor, nucleic acids encoding the same, and methods of use therefor. More preferably, the novel designer osteogenic proteins are designer BMPs and have altered affinity for a cognate BMP receptor. The designer BMPs demonstrate altered biological characteristics and provide potential useful novel therapeutics.Type: GrantFiled: December 6, 2018Date of Patent: May 18, 2021Assignee: Wyeth, LLC.Inventors: Stephen Berasi, Robert Vincent Martinez, Michael John Cain, John Martin Wozney, Howard Seeherman, Zong Sean Juo, Valerie Perrine Calabro, Christopher Todd Brown
-
Patent number: 11001833Abstract: A combined ribosome-display and phage-display method and kit for carrying out the method are provided. The method includes screening a ribosome-display library of binding agents to identify binding agents that interact with one or more target molecules of interest, converting the RNA encoding the binding agents to a phage-display format by amplification and primer extension, and the screening the phage-display library to enrich for binding agents that interact with one or more target molecules of interest.Type: GrantFiled: August 27, 2018Date of Patent: May 11, 2021Assignee: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOISInventors: Michael Kierny, Brian Kay
-
Patent number: 10995347Abstract: The invention provides methods for improving efficiency of fermentation by arginine supplementation, and genetically modified bacterium for use therefor. More particularly the invention provides methods for (i) increasing the production ATP intensive products with arginine supplementation, (ii) increasing utilization of arginine by a C1-fixing bacterium; and (iii) providing C1-fixing bacterium with optimized arginine de-aminase pathways.Type: GrantFiled: December 2, 2016Date of Patent: May 4, 2021Assignee: LANZATECH NEW ZEALAND LIMITEDInventors: Michael Koepke, James Bruce Yarnton Haycock Behrendorff, Kaspar Valgepea, Esteban Marcellin, Lars K. Nielsen, Renato de S.P. Lemgruber
-
Patent number: 10994047Abstract: Peptide dendrimers and agents are described, which can be used for polymerising fibrinogen and as haemostatic agents. The peptide dendrimers comprise a branched core, and a plurality of fibrinogen-binding peptides separately covalently attached to the branched core.Type: GrantFiled: January 8, 2015Date of Patent: May 4, 2021Assignee: HAEMOSTATIX LIMITEDInventor: Renata Zbozien
-
Patent number: 10995326Abstract: Provided is a method for safely and selectively producing a substrate culture product including a large amount of a desired degrading enzyme. A method for producing a substrate culture product used for feedstuff includes inoculating filamentous fungi bred so that a target degrading enzyme is produced by self-cloning in high productivity on a substrate, and producing the substrate culture product having functionality by ventilating the substrate to carry out solid culture.Type: GrantFiled: September 30, 2019Date of Patent: May 4, 2021Assignee: FUJIWARA TECHNO-ART CO., LTD.Inventors: Masahiro Kariyama, Akira Mori, Satoko Takahashi
-
Patent number: 10988730Abstract: The invention relates to a lyophilisate or to a powder including i) at least one globin, a globin protomer or an extracellular hemoglobin from annelids, and ii) at least one biological material from annelids that is different from said globin, from said protomer and from said hemoglobin.Type: GrantFiled: May 14, 2014Date of Patent: April 27, 2021Assignee: HemarinaInventor: Franck Zal
-
Patent number: 10987369Abstract: A Pdia4 inhibitor for use in preventing, alleviating and/or treating diabetes and/or diabetes-related complications in a subject in need thereof is disclosed, wherein the Pdia4 inhibitor does not comprise cytopiloyene. A Pdia4 inhibitor and one other anti-diabetic agent for use in combination therapy in preventing, alleviating, treating diabetes and diabetes-related complications, and/or reversing diabetes in a subject in need thereof is also disclosed, wherein the Pdia4 inhibitors for use in combination therapy may comprise cytopiloyene. Also disclosed are methods for diagnosing, treating and monitoring diabetes, and methods of screening for a Pdia4 inhibitor and/or an anti-diabetic agent.Type: GrantFiled: April 9, 2015Date of Patent: April 27, 2021Assignee: ACADEMIA SINICAInventors: Wen-Chin Yang, Lee-Tian Chang
-
Patent number: 10982222Abstract: Provided are isolated polynucleotides, polypeptides encoded thereby, nucleic acid constructs comprising same, plant cells and plants comprising same and methods of generating plants with increased yield, biomass, growth rate, vigor, oil content, fiber yield, fiber quality, abiotic stress tolerance, and/or nitrogen use efficiency, wherein the polynucleotides encode polypeptides at least 80% identical to SEQ ID NO: 574-930, 6266-10549 or 10550, such as the polynucleotides set forth in SEQ ID NOs:1-573, and 931-6265.Type: GrantFiled: October 10, 2017Date of Patent: April 20, 2021Assignee: Evogene Ltd.Inventors: Limor Poraty-Gavra, Ilya Pankratov, Hagai Karchi
-
Patent number: 10980870Abstract: Nucleic acid molecules which encode an MRSA PBP2a protein or a fragment thereof which comprises at least 245 amino acid are disclosed. Compositions comprising the nucleic acid molecules are disclosed. Novel proteins which comprise a MRSA PBP2a protein or a fragment thereof which comprises at least 245 amino acid are disclosed are disclosed. Methods of inducing an immune response against MRSA PBP2a are disclosed, as are methods of treating an individual who has been diagnosed with MRSA and methods of preventing MRSA infection in an individual.Type: GrantFiled: August 24, 2018Date of Patent: April 20, 2021Assignee: The Trustees of the University of PennsylvaniaInventors: David B. Weiner, Matthew P. Morrow
-
Patent number: 10982242Abstract: The present invention relates to an optimized fermentation process of coenzyme Q10, particularly to a fermentation process of coenzyme Q10 via flow feeding based on cooperative control of changes of online oxygen consumption rate and conductivity. During the fermentation process of coenzyme Q10 production strains, the oxygen consumption rate is controlled between 30-150 mmol/L·h and the conductivity is maintained between 3.0-30.0 ms/cm via flow feeding, so as to facilitate strain growth and the start of coenzyme Q10 synthesis and accumulation. The present invention can substantially increase output of coenzyme Q10 and greatly reduce the production cost with simple process control and strong operability, thus being applicable to large-scale industrial production.Type: GrantFiled: October 21, 2016Date of Patent: April 20, 2021Assignees: SHANGYU NHU BIOLOGICAL CHEMICAL CO., LTD., ZHEJIANG UNIVERSITY, ZHEJIANG NHU COMPANY LTD.Inventors: Hongwei Yu, Yong Lv, Yong Li, Jianbo Chen, Shaofeng Chen, Weifeng Li, Hongmei Zhang, Yongqiang Zhu